Articles from Nutriband Inc.

ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark "Nutriband™." The Trademark registration covers Goods/Services: Class: 042 Product research and development, scientific research and development; biochemical research and development; pharmaceutical research and development.

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments

ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita has been appointed to its Product Advisory Board to expand the Nutriband Brand and promote it’s over the counter sports and consumer products internationally.

The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia

ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company’s achievements in 2024 and the outlook for 2025.

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for first half of 2025.

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.

AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch

ORLANDO, FL / ACCESSWIRE / July 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 7:6 forward split of its common stock that is expected to be effective at 12:01AM on August 15 and in effect at the opening of trading on Monday August 15, 2022.

ORLANDO, FL / ACCESSWIRE / July 26, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it has received the Final Judgment in favor of the company, effectively allowing the company to cancel 1.2M shares held by the defendants in the Court case filed in Orlando, Florida, by the Company. The shares in question equate to approximately 15% of the Company's shares now outstanding.

ORLANDO, FL / ACCESSWIRE / July 22, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) is pleased to announce the opening of its new branch in Quito, Ecuador. The Company plans to expand its product offering to the region through product registration and contract services.

ORLANDO, FL / ACCESSWIRE / July 15, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that it has received a verdict in favor of the company, where the company prevailed on all issues, relating to the lawsuit the company filed to rescind the acquisition of Advanced Health Brands in 2017.

New proposed guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications

ORLANDO, FL / ACCESSWIRE / May 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, contract research and development services and the contract manufacture services today announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report® on Bloomberg TV, May 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

Nutriband Inc. Invites Individual and Institutional Investors As Well as Advisors and Analysts, To Attend Its Real-Time, Interactive Presentation at the Emerging Growth Conference

ORLANDO, FL / ACCESSWIRE / May 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today it has booked nearly a quarter of a million dollars in new in contract manufacturing orders through its wholly-owned subsidiary Pocono Pharma, extending its current run of record-breaking revenue. The reported amount of the orders, which is just over $234,000, exceeds the revenue reported for the entire Q2 of 2021. "Continuing to build on our

Class 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC ORLANDO, FL / ACCESSWIRE / May 11, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced its Active Intelligence LLC subsidiary has registered as a Class I medical device manufacturer with the U.S. Food and Drug

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

ORLANDO, FL / ACCESSWIRE / February 16, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. US Patent 11,246,840 dated Feb 15, 2022 underpins 4P Therapeutics' abuse deterrent transdermal system, AVERSA™, which uses taste

ORLANDO, FL / ACCESSWIRE / February 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) will be participating in the Benzinga ALL ACCESS, which will take place on February 4. Nutriband CEO, Gareth Sheridan will be speaking at 10AM ET. You can watch it live at https://www.youtube.com/watch?v=eC4RGvgx9aQ. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product

ORLANDO, FL / ACCESSWIRE / January 28, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United States Patent and Trademark Office (USPTO) for its United States patent entitled, "Abuse and Misuse Deterrent Transdermal System," that protects its AVERSA™ transdermal abuse deterrent technology. Nutriband's AVERSA™ abuse deterrent technology can be utilized to incorporate

ORLANDO, FL / ACCESSWIRE / January 18, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology. The AVERSA abuse deterrent technology platform can be applied to any transdermal patch that has a risk of abuse, misuse or accidental exposure. It is based on incorporating aversive agents into the patch that do not contact the drug

ORLANDO, FL / ACCESSWIRE / January 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband's lead product, AVERSA™ Fentanyl, based on its proprietary AVERSA™ abuse deterrent transdermal technology and Kindeva's FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement is focused on adapting

ORLANDO, FL / ACCESSWIRE / January 5, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products has completed the market assessment and commercialization strategy for its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market opportunity and

ORLANDO, FL / ACCESSWIRE / December 31, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Korean Intellectual Property Office (KIPO) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of

ORLANDO, FL / ACCESSWIRE / December 29, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the Company had 7,773,962 shares of common stock outstanding. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent

ORLANDO, FL / ACCESSWIRE / December 21, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced plans to start offering contract manufacturing services for liquid based topical, transdermal and cosmetic product's.This follows the recent certification as a cGMP facility following a

ORLANDO, FL / ACCESSWIRE / December 13, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its manufacturing subsidiary Active Intelligence, has received cGMP certification following a full cGMP audit. The audit was conducted specifically in relation to the certification of

ORLANDO, FL / ACCESSWIRE / December 3, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its Chief Executive Officer Gareth Sheridan and President Serguei Melnik will be joined by members of the Company's board of directors and senior management to ring the NASDAQ Stock

ORLANDO, FL / ACCESSWIRE / November 16, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, has commenced the development of its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system. Following the Company's recent successful uplisting to NASDAQ and

ORLANDO, FL / ACCESSWIRE / November 10, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal, topical and coated products, today announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report® on Bloomberg TV, November 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available

ORLANDO, FL / ACCESSWIRE / October 22, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, is pleased to announce the receipt of $2,062,500 in additional gross from the exercise of warrants issued in the Company's October 1, 2021 public offering of securities. Investors participating in

ORLANDO, FL / ACCESSWIRE / October 12, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products, today announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals to monitor for the presence of antibodies

ORLANDO, FL / ACCESSWIRE / October 4, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application 16/707,547, entitled 'Abuse

ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermal products, today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market effective October 1, 2021. Nutriband also